AAAAAA
Results: 1-25/26
Authors:
SCANLON KJ
KASHANISABET M
Citation: Kj. Scanlon et M. Kashanisabet, RIBOZYMES AS THERAPEUTIC AGENTS - ARE WE GETTING CLOSER, Journal of the National Cancer Institute, 90(8), 1998, pp. 558-559
Authors:
IRIE A
ENGEBRAATEN O
ANDEREGG B
FLORL A
HALKSMILLER M
SCANLON KJ
KASHANISABET M
Citation: A. Irie et al., ADENOVIRAL MEDIATED ANTI-H-RAS RIBOZYME FOR THE TREATMENT OF BLADDER-CANCER, The Journal of urology, 159(5), 1998, pp. 1106-1106
Authors:
KIJIMA H
TSUCHIDA T
KONDO H
IIDA T
OSHIKA Y
NAKAMURA M
SCANLON KJ
KONDO T
TAMAOKI N
Citation: H. Kijima et al., HAMMERHEAD RIBOZYMES AGAINST GAMMA-GLUTAMYLCYSTEINE SYNTHETASE MESSENGER-RNA DOWN-REGULATE INTRACELLULAR GLUTATHIONE CONCENTRATION OF MOUSEISLET CELLS, Biochemical and biophysical research communications (Print), 247(3), 1998, pp. 697-703
Authors:
OHKAWA T
SCANLON KJ
Citation: T. Ohkawa et Kj. Scanlon, DELIVERY SYSTEMS OF AN ANTI-H-RAS HAMMERHEAD RIBOZYME AGAINST HUMAN-MALIGNANT MELANOMA, Cancer gene therapy, 4(1), 1997, pp. 69-69
Authors:
CURCIO LD
BOUFFARD DY
SCANLON KJ
Citation: Ld. Curcio et al., OLIGONUCLEOTIDES AS MODULATORS OF CANCER GENE-EXPRESSION, Pharmacology & therapeutics, 74(3), 1997, pp. 317-332
Authors:
BOUFFARD DY
OHKAWA T
KIJIMA H
IRIE A
SUZUKI T
CURCIO LD
HOLM PS
SASSANI A
SCANLON KJ
Citation: Dy. Bouffard et al., OLIGONUCLEOTIDE MODULATION OF MULTIDRUG-RESISTANCE, European journal of cancer, 32A(6), 1996, pp. 1010-1018
Authors:
SOBOL RE
SCANLON KJ
Citation: Re. Sobol et Kj. Scanlon, CANCER GENE-THERAPY - CLINICAL PERSPECTIVE 1995, Cancer gene therapy, 3(1), 1996, pp. 3-3
Authors:
SCANLON KJ
KIJIMA H
ISHIDA H
Citation: Kj. Scanlon et al., REVERSAL OF DRUG-RESISTANCE IN HUMAN CARCINOMAS BY ANTIONCOGENE RIBOZYMES, Cytotechnology, 19(3), 1996, pp. 257-289
Authors:
ZHANG YA
NEUMUNAITIS J
MUES G
SCANLON KJ
TONG AW
Citation: Ya. Zhang et al., IN-VITRO SUPPRESSION OF HUMAN NON-SMALL-CELL LUNG-CANCER (NSCLC) CELL-GROWTH BY AN ANTI-K-RAS RIBOZYME, The FASEB journal, 10(6), 1996, pp. 2360-2360
Authors:
JIAO L
XIA L
HORNG M
KASHFIAN BI
KASHANISABET M
SCANLON KJ
Citation: L. Jiao et al., ONCOGENE EXPRESSION IN MULTIDRUG-RESISTANT OVARIAN CARCINOMAS, Onkologie, 19, 1996, pp. 19-22
Authors:
OHTA Y
KIJIMA H
OHKAWA T
KASHANISABET M
SCANLON KJ
Citation: Y. Ohta et al., TISSUE-SPECIFIC EXPRESSION OF AN ANTI-RAS RIBOZYME INHIBITS PROLIFERATION OF HUMAN-MALIGNANT MELANOMA-CELLS, Nucleic acids research, 24(5), 1996, pp. 938-942
Authors:
OHTA Y
KASHANISABET M
SCANLON KJ
Citation: Y. Ohta et al., SUPPRESSION OF ME MALIGNANT PHENOTYPE OF MELANOMA-CELLS BY ANTIONCOGENE RIBOZYMES, Journal of investigative dermatology, 106(4), 1996, pp. 572-572
Authors:
OHTA Y
KIJIMA H
KASHANISABET M
SCANLON KJ
Citation: Y. Ohta et al., SUPPRESSION OF THE MALIGNANT PHENOTYPE OF MELANOMA-CELLS BY ANTIONCOGENE RIBOZYMES, Journal of investigative dermatology, 106(2), 1996, pp. 275-280
Authors:
MAELANDSMO GM
HOVIG E
SKREDE M
ENGEBRAATEN O
FLORENES VA
MYKLEBOST O
GRIGORIAN M
LUKANIDIN E
SCANLON KJ
FODSTAD O
Citation: Gm. Maelandsmo et al., REVERSAL OF THE IN-VIVO METASTATIC PHENOTYPE OF HUMAN TUMOR-CELLS BY AN ANTI-CAPL (MTS1) RIBOZYME, Cancer research, 56(23), 1996, pp. 5490-5498
Authors:
KASHANISABET M
SCANLON KJ
Citation: M. Kashanisabet et Kj. Scanlon, APPLICATION OF RIBOZYMES TO CANCER GENE-THERAPY, Cancer gene therapy, 2(3), 1995, pp. 213-223
Authors:
SOBOL RE
SCANLON KJ
Citation: Re. Sobol et Kj. Scanlon, CANCER GENE-THERAPY CLINICAL-TRIALS, Cancer gene therapy, 2(1), 1995, pp. 5-6
Authors:
SCANLON KJ
OHTA Y
ISHIDA H
KIJIMA H
OHKAWA T
KAMINSKI A
TSAI J
HORNG G
KASHANISABET M
Citation: Kj. Scanlon et al., OLIGONUCLEOTIDE-MEDIATED MODULATION OF MAMMALIAN GENE-EXPRESSION, The FASEB journal, 9(13), 1995, pp. 1288-1296
Authors:
KIJIMA H
ISHIDA H
OHKAWA T
KASHANISABET M
SCANLON KJ
Citation: H. Kijima et al., THERAPEUTIC APPLICATIONS OF RIBOZYMES, Pharmacology & therapeutics, 68(2), 1995, pp. 247-267
Authors:
FENG M
CABRERA G
DESHANE J
SCANLON KJ
CURIEL DT
Citation: M. Feng et al., NEOPLASTIC REVERSION ACCOMPLISHED BY HIGH-EFFICIENCY ADENOVIRAL-MEDIATED DELIVERY OF AN ANTI-RAS RIBOZYME, Cancer research, 55(10), 1995, pp. 2024-2028
Authors:
HILL BT
SCANLON KJ
HANSSON J
HARSTRICK A
PERA M
FICHTINGERSCHEPMAN AMJ
SHELLARD SA
Citation: Bt. Hill et al., DEFICIENT REPAIR OF CISPLATIN-DNA ADDUCTS IDENTIFIED IN HUMAN TESTICULAR TERATOMA CELL-LINES ESTABLISHED FROM TUMORS FROM UNTREATED PATIENTS, European journal of cancer, 30A(6), 1994, pp. 832-837
Authors:
SOBOL RE
SCANLON KJ
Citation: Re. Sobol et Kj. Scanlon, UNTITLED - EDITORIAL, Cancer gene therapy, 1(1), 1994, pp. 3-3
Authors:
TAVERNA P
HANSSON J
SCANLON KJ
HILL BT
Citation: P. Taverna et al., GENE-EXPRESSION IN X-IRRADIATED HUMAN TUMOR-CELL LINES EXPRESSING CISPLATIN RESISTANCE AND ALTERED DNA-REPAIR CAPACITY, Carcinogenesis, 15(9), 1994, pp. 2053-2056
Authors:
SCANLON KJ
ISHIDA H
KASHANISABET M
Citation: Kj. Scanlon et al., RIBOZYME-MEDIATED REVERSAL OF THE MULTIDRUG-RESISTANT PHENOTYPE, Proceedings of the National Academy of Sciences of the United Statesof America, 91(23), 1994, pp. 11123-11127
Authors:
KASHANISABET M
FUNATO T
FLORENES VA
FODSTAD O
SCANLON KJ
Citation: M. Kashanisabet et al., SUPPRESSION OF THE NEOPLASTIC PHENOTYPE IN-VIVO BY AN ANTI-RAS RIBOZYME, Cancer research, 54(4), 1994, pp. 900-902
Authors:
HOLM PS
SCANLON KJ
DIETEL M
Citation: Ps. Holm et al., REVERSION OF MULTIDRUG-RESISTANCE IN THE P-GLYCOPROTEIN-POSITIVE HUMAN PANCREATIC-CELL LINE (EPP85-181RDB) BY INTRODUCTION OF A HAMMERHEAD RIBOZYME, British Journal of Cancer, 70(2), 1994, pp. 239-243